GlassScriptPhysician profile
Alessandra Bertolucci
NPI 1174528996
$3,718.98
in general payments reported to CMS, 2019-2025
24 companies · $690 in 2025
The $690 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $685 · 2020: $434 · 2021: $602 · 2022: $460 · 2023: $523 · 2024: $326 · 2025: $690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.17 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $501.64 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $489.31 | 2019-2021 | |
| Abbvie INC. | $470.03 | 2022-2025 | Durysta, Alphagan P, Vuity |
| Bausch & Lomb Americas INC. | $436.48 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Regeneron Healthcare Solutions, INC. | $413.24 | 2019-2025 | Eylea Hd |
| Aerie Pharmaceuticals, INC. | $272.80 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $173.27 | 2019-2024 | Cequa, Xelpros, Bromsite |
| Harrow Eye, LLC | $124.47 | 2025 | Triesence, Iheezo |
| Biotissue Holdings INC. | $120.68 | 2019-2022 | |
| Astellas Pharma US INC | $97.34 | 2023-2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $92.69 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $92.58 | 2024-2025 | Xdemvy |
| Coherus Oncology, INC. | $87.34 | 2023 | |
| Alimera Sciences, INC. | $85.24 | 2021 | |
| Alcon Vision LLC | $76.28 | 2022-2025 | Rocklatan |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $36.00 | 2023-2024 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $32.14 | 2022-2025 | Syfovre |
| Shire North American Group INC | $27.76 | 2019 | |
| Eyevance Pharmaceuticals LLC | $17.99 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $15.04 | 2021 | |
| Spark Therapeutics, INC. | $14.95 | 2020 | |
| Dompe US, INC. | $14.74 | 2020 | |
| Kala Pharmaceuticals, INC. | $13.51 | 2021 | |
| Horizon Therapeutics Plc | $13.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alessandra Bertolucci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.